Sentence examples for efficient prescribing from inspiring English sources

Even more than a decade later, the National Audit Office NAOO) report concerning prescribing costs in primary care in the UK in 2007 [ 33] found that a potential cost saving of more than GB£200 million a year could be achieved, without compromising the quality of care, through efficient prescribing in four therapeutic drug classes, including RAS drugs.

Apart from the NAO estimated cost saving figures from efficient prescribing of RAS drugs, little is known about the actual impact of BCBV prescribing indicator on ACEIs/ARBs utilisation and cost-savings.

Efficient prescribing and the minimisation of risk for patients can be supported and upgraded by educational barriers (classification for physicians) and information methods.

The efficient prescribing of RAS agents has been under intensive scrutiny in many European countries and regions, ex.

In the interests of identifying factors that could lead to more efficient prescribing, three cantons were selected, one from each linguistic region of Switzerland.

Therefore, efficient prescribing of RAS agents, i.e., prescribing cheaper generic ACEIs instead of more expensive patent protected ARBs, is considered an important cost-saving strategy.

However, the opportunity of a potential saving is still possible via enhancement of efficient ACEIs/ARBs prescribing in NHS primary care practices, even after narrowing the cost differential between ACEIs and ARBs.

This study adds to existing data demonstrating a widespread problem with prescribing for which there appears to be no consensus on the instructional designs that will ensure patient safety through efficient and effective prescribing [ 9].

Understanding the characteristics of early adopters may help to speed up the diffusion process, promote cost-efficient prescribing habits, forecast utilisation, and develop targeted intervention strategies.

Doctors could also contribute towards more efficient medicine by prescribing formulations that facilitate therapeutic compliance only in patients who have shown poor treatment adherence.

Importantly, although the potential cost-saving of efficient ACEIs/ARBs prescribing was moderated by the availability of generic ARBs, the analysis of June 2014 PCA data indicated that the failure of achieving the 80 % ACEIs target in June 2014 resulted in losing (8.7 %, GB£92,688,486) a potential cost-savings opportunity in the total ACEIs/ARBs costs (GB£1.06 billion).